Arecor Receive Payment After Milestone Achieved
Arecor’s ongoing progress from their licensed platform Arestat™ triggers milestone payment from Inhibrx Inc.
Arecor’s ongoing progress from their licensed platform Arestat™ triggers milestone payment from Inhibrx Inc.
Calculus Capital’s investment director, Liz Klein, to discuss the dynamic world where capital meets compassion.
Laverock Therapeutics secures £1m funding via the Innovate UK Investor Partnerships Future Economy programme, supported by UKI2S
Richard Moore, Co-Head of Investments, gives his analysis on how a higher bank rate may affect the investment decisions made, and his outlook for the portfolio.
Oxford BioTherapeutics’s partner has dosed first patient in phase 2 trial that has potential to revolutionise treatment.
Wonderhood have been commissioned to produce a second season of Super Surgeons: A Chance at Life.
Laverock Therapeutics to demonstrate breadth of therapeutic applications of gene silencing platform at European Society of Gene & Cell Therapy.
Artificial Intelligence (AI), has emerged as a disruptive force with the potential to revolutionise industries across the globe. For investors and shareholders, AI represents a compelling opportunity.
Open Energy Market, Calculus portfolio company and a leading provider of energy procurement services and Net Zero technologies, has introduced a pioneering platform called True, which combines an organisation’s actual energy procurement costs with its Net Zero strategies.
Calculus has led an investment round into Laverock Therapeutics, a company developing a unique gene silencing platform for the creation of programmable advanced therapies.